Systemic immune dysfunction in pancreatic cancer patients
Systemic immune dysfunction in pancreatic cancer patients
复制标题
DOI:
10.1007/s00423-006-0140-7
复制
发表时间:
2007-05-01
影响因子:
2.3
通讯作者:
Gansauge, Frank
中科院分区:
文献类型:
--
作者:
Poch, Bertram;Lotspeich, Errki;Gansauge, Frank
Background and aims We investigated the immune status in 32 pancreatic cancer patients (PC) in comparison with healthy controls (HC).Materials and methods Using flow cytometry, peripheral blood lymphocytes (PBL) were characterized by the expression of surface markers for T helper cells (CD4), T suppressor cells (CD8), B cells (CD19) and NK cells (CD56). The blastogenic response of PBL was analyzed after stimulation with concavalin A (ConA), phytohemagglutinin (PHA), pokeweed mitogen (PWM) and anti-CD3 antibodies. The serum levels of TNF-alpha, IL-1 beta, IL-2, IL-10, IL-12, IL-18, IL-1RA, sIL-2R and TGF-beta were determined by ELISA.Results No differences in the distribution of peripheral immunocytes in PC were found, whereas the blastogenic response of peripheral blood lymphocytes (PBL) after stimulation with PHA or anti-CD3 antibodies was significantly decreased in PC. In PC, we found reduced serum levels of IL-2 and significantly elevated levels of TNF-alpha, TGF-beta 1, IL-10, IL-2R, IL-1 beta and IL-1RA.Conclusion These data provide evidence for a systemic immune dysfunction in pancreatic cancer patients characterized by a shift towards a T helper cell type 2 cytokine profile, a significant elevation of substances related to T cell suppression and a reduced blastogenic response to PHA and anti-CD3 antibodies of PBL.